The Wegovy Maintenance Dose: What It Actually Means

The misconception worth clearing up first

A lot of people come to the maintenance dose expecting it to feel like a finish line — as if once you are there, the medicine is simply ticking over in the background. That is understandable, but it is not quite right. The maintenance dose is the therapeutic dose. The weeks spent at 0.25 mg, 0.5 mg, 1.0 mg and 1.7 mg were about preparing your body to tolerate 2.4 mg comfortably, not about meaningful weight loss in themselves.

The clinical trials that led to Wegovy's UK licence were powered at the 2.4 mg level. In the STEP 1 study, published in the New England Journal of Medicine, participants lost around 15% of their body weight on average over 68 weeks, the vast majority of that during and after reaching maintenance. So the dose you spend most of your time on is also the one doing most of the lifting. Worth knowing before you reach it.

There is one more thing that often surprises people: the appetite reduction does not suddenly switch on at 2.4 mg. For many, it builds gradually across the titration steps, and if you are curious about what the Wegovy pen looks like after the first dose, that can help you understand what to expect as you work through the early stages. But it reliably intensifies once the body is exposed to the full maintenance dose consistently, week after week.

What the dose schedule actually looks like

Wegovy starts at 0.25 mg once weekly. Every four weeks or so, your prescriber steps the dose up, to 0.5 mg, then 1.0 mg, then 1.7 mg, and finally 2.4 mg. That is the standard Wegovy dosing pathway as set out in the medicine's licensed schedule. The whole titration phase takes around sixteen to twenty weeks before you are established on 2.4 mg.

For some people, the journey does not stop there. The MHRA approved a 7.2 mg maintenance dose in early 2026, initially via three 2.4 mg pens weekly, and later via a dedicated single-dose pen approved on 14 April 2026, the first of its kind. The 7.2 mg option is licensed for adults with a BMI of 30 or above. Trial data reported average weight loss of around 20.7% over 72 weeks at this dose, which narrows the gap with tirzepatide's highest-dose results considerably. Availability and suitability for that dose is something to discuss with a prescriber at the appropriate stage, it is not a starting point, and it is not right for everyone.

You can read more about how the Wegovy maintenance dose is managed in practice, including what a prescriber looks for before confirming you are ready to stay at your current level.

Do you keep losing weight once you reach maintenance?

For most people, yes, weight loss continues after reaching 2.4 mg, often for many months. The body's response takes time, and the full effect of GLP-1 receptor agonism on appetite regulation builds with consistent exposure. This is one reason the relationship between dose and weight loss is not linear in the way people sometimes expect.

There is a nuance here that the NHS and NICE guidance both acknowledge: if you have not lost at least 5% of your starting body weight after six months on the maintenance dose, your prescriber should review whether continuing makes sense. That threshold is a clinical decision point, not an automatic cut-off. It appears in NICE's technology appraisal for semaglutide (TA875) and shapes how NHS prescribers assess ongoing benefit.

For people doing well at maintenance, the trajectory typically plateaus over time, that is normal. The medicine suppresses appetite; it does not continue to accelerate weight loss indefinitely. Many people find the plateau arrives between twelve and twenty-four months. What happens after that, including what evidence exists on keeping weight off, is a conversation for your prescriber rather than something to try to manage alone. You can also explore what losing weight on the Wegovy maintenance dose looks like in more detail.

How a prescriber decides your maintenance dose is right for you

The dose that appears on your prescription is not the same for everyone, even if most people end up at 2.4 mg. A prescriber reviewing your case looks at how you have responded at each titration step: side-effect burden, weight-loss trajectory, any relevant health conditions, and whether there are reasons to pause, hold a lower dose for longer, or consider the higher 7.2 mg option once it is clinically appropriate.

At nume, a GPhC-registered prescriber personally reviews your case before every repeat, including before any dose change. There is no auto-advancement. If a dose increase needs clinical evidence, we ask for it. That is not bureaucracy, it is the part of the process that keeps you safe, and it is a standard our clinical team applies consistently.

Wegovy is a prescription-only medicine. The right maintenance dose is determined through clinical assessment, not by reading about it online. If you are considering treatment and want to understand whether Wegovy might be suitable for your situation, our Wegovy overview is a good place to start, or you can browse weight-loss treatment options more broadly. When you are ready to take the next step, you can start your free consultation and have your case reviewed by one of our prescribers the same day.